BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Citi
Dow
Chubb
Argus Health
Moodys
Deloitte
Fuji
Express Scripts
Julphar

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,828,320

« Back to Dashboard

Which drugs does patent 6,828,320 protect, and when does it expire?

Patent 6,828,320 protects TYKERB and is included in one NDA.

This patent has fifteen patent family members in fourteen countries.
Summary for Patent: 6,828,320
Title: Heterocyclic compounds
Abstract:Substituted heteroaromatic compounds, and in particular substituted quinolines and quinazolines, are protein tyrosine kinase inhibitors. The compounds are described as are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine, for example in the treatment of cancer and psoriasis.
Inventor(s): Cockerill; George Stuart (Bedford, GB), Carter; Malcolm Clive (Ware, GB), Guntrip; Stephen Barry (Hertford, GB), Smith; Kathryn Jane (Bishop's Stortford, GB)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:10/062,647
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,828,320

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms Corp TYKERB lapatinib ditosylate TABLET;ORAL 022059-001 Mar 13, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR ➤ Subscribe
Novartis Pharms Corp TYKERB lapatinib ditosylate TABLET;ORAL 022059-001 Mar 13, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,828,320

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9614755Jul 13, 1996
United Kingdom9625458Dec 07, 1996

Non-Orange Book US Patents Family Members for Patent 6,828,320

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,391,874 Fused heterocyclic compounds as protein tyrosine kinase inhibitors ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,828,320

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 007857 ➤ Subscribe
Austria 227283 ➤ Subscribe
Australia 3766897 ➤ Subscribe
Cyprus 2451 ➤ Subscribe
Germany 69716916 ➤ Subscribe
Denmark 0912559 ➤ Subscribe
European Patent Office 0912559 ➤ Subscribe
Spain 2186908 ➤ Subscribe
United Kingdom 9614755 ➤ Subscribe
United Kingdom 9625458 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
QuintilesIMS
Colorcon
Healthtrust
US Department of Justice
Julphar
AstraZeneca
Covington
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot